Literature DB >> 19388579

Phenotypic and molecular epidemiology of Acinetobacter baumannii strains isolated in Rabta Hospital, Tunisia.

A Ben Othman1, M Zribi, A Masmoudi, S Abdellatif, S Ben Lakhal, C Fendri.   

Abstract

Acinetobacter baumannii (A. baumannii) is often implicated in hospital outbreaks in Tunisia. It's a significant opportunistic pathogen that is usually associated with serious underlying diseases such as pneumoniae, meningitis and urinary tract infections. The aim of this prospective study was to evaluate the global state of its endemicity and the antibiotic resistance evolution. The possibility of nosocomial transmission of one or more epidemic strain(s) was investigated by means of 3 methods: biotyping, antibiotyping and Random Amplified Polymorphic DNA analysis (RAPD). MIC for imipenem by Ellipsometer-test strip (E-TEST). The presence of metallo-beta-lactamases (MBL) was detected according to the double synergy test of EDTA and imipenem disks. A. baumannii strains were mainly localized in intensive care (52.2%) and surgery units (23.6%). Among 224 strains that were studied, 4 biotypes were delineated with a predominance of biotype1. Resistance to beta-lactams was mostly associated with the production of cephalosporinases and penicilinases (84.3%). 45% of strains were resistant to imipenem which were associated with MBL production. RAPD gave 5 genomic groups. This study demonstrates the epidemic behaviour airborne spread of A. baumannii in hospital wards. The multiresistance was often responsible for failure of antibiotics therapy. The prevention of nosocomial infection and severe hygiene controls must be performed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19388579

Source DB:  PubMed          Journal:  Arch Inst Pasteur Tunis        ISSN: 0020-2509


  1 in total

1.  Role of plasmid carrying bla NDM in mediating antibiotic resistance among Acinetobacter baumannii clinical isolates from Egypt.

Authors:  Alaa Abouelfetouh; Aisha S Torky; Elsayed Aboulmagd
Journal:  3 Biotech       Date:  2020-03-16       Impact factor: 2.406

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.